Construction of colorectal cancer prognostic survival prediction model based on RNA-seq data of immune genes

doi:10.3877/cma.j.issn.2095-3224.2021.06.004

Abstract

Abstract:

Objective

To screen the immune genes related to the prognosis of colorectal cancer and construct a prognostic prediction model.

Methods

Collect immune-related genes from the ImmPort database. The Colon adenocarcinoma (COAD) dataset from The Cancer Genome Atlas (TCGA) database is used to identify prognostic gene features and construct a prognostic survival prediction model, which is validated in the Gene Expression Omnibus (GEO) dataset. Perform gene function enrichment analysis.

Results

A total of 362 immune-related genes that were differentially expressed in patients with colorectal cancer were obtained by differential expression analysis; Thirty-two prognostic-related immune genes were obtained from single-factor COX regression screening. The result of functional enrichment showed that they were related to T cell-mediated immunity. The up-regulation of cell-mediated cytotoxicity was positively correlated; multi-factor COX regression finally determines that SCTR, XCL1, NGF, CD1B, and EREG were the key prognostic risk immune genes for colorectal cancer. The prognostic survival prediction model constructed by 5 genes was used for colorectal cancer. The prognosis of cancer patients has a good predictive rate.

Conclusion

Five-gene characteristics related to immunity are reliable prognostic indicators for patients with COAD and can provide insights for personalized cancer management.

Key words: Colorectal neoplasms, Immunity, Prediction model, Gene signature, Prognosis

Weihua Li, Pengyu Zhao, Hongjian Li, Linjiang Liu, Yunjie Li, Fang Zhang, Haijun Zou, Yuli Wang. Construction of colorectal cancer prognostic survival prediction model based on RNA-seq data of immune genes[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(06): 585-590.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2021.06.004

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2021/V10/I06/585

Figures/Tables 6

References 20

[1]	Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, Version 2.2018[J]. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16(4): 359-369.
[2]	Chen WQ, Li H, Sun KX, et al. Report of Cancer Incidence and Mortality in China, 2014[J]. Chinese Journal of Oncology, 2018, 40(1): 5-13.
[3]	Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2015, 33(16): 1787-1796.
[4]	Frampton M, Houlston RS. Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors[J]. Genetics in medicine: official journal of the American College of Medical Genetics, 2017, 19(3): 314-321.
[5]	Croci DO, Zacarías Fluck MF, Rico MJ, et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment[J]. Cancer immunology, immunotherapy: CII. 2007, 56(11): 1687-1700.
[6]	Broussard EK, Kim R, Wiley JC, et al. Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions[J]. Cancer prevention research (Philadelphia, Pa.), 2013, 6(7): 666-674.
[7]	O'Connell J, Bennett MW, Nally K, et al. Altered mechanisms of apoptosis in colon cancer: fas resistance and counterattack in the tumor-immune conflict[J]. Annals of the New York Academy of Sciences, 2000, 910:178-192; discussion 193-175.
[8]	Tauriello DVF, Palomo-Ponce S, Stork D, et al. Tgfβ drives immune evasion in genetically reconstituted colon cancer metastasis[J]. Nature, 2018, 554(7693): 538-543.
[9]	Abbas AR, Baldwin D, Ma Y, et al. Immune response in silico (iris): immune-specific genes identified from a compendium of microarray expression data[J]. Genes and immunity, 2005, 6(4): 319-331.
[10]	Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project[J]. Nature genetics, 2013, 45(10): 1113-1120.
[11]	Bhattacharya S, Dunn P, Thomas CG, et al. Immport, toward repurposing of open access immunological assay data for translational and clinical research[J]. Scientific data, 2018, 5: 180015.
[12]	Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for Rna-Seq data with Deseq2[J]. Genome biology, 2014, 15(12): 550.
[13]	Yu G, Wang LG, Han Y, et al. Clusterprofiler: an r package for comparing biological themes among gene clusters[J]. Omics: a journal of integrative biology, 2012, 16(5): 284-287.
[14]	Gene Ontology Consortium. Gene Ontology Consortium: going forward[J]. Nucleic Acids Res, 2015, 43 (Database issue): D1049-1056.
[15]	Goel MK, Khanna P, Kishore J. Understanding Survival Analysis: Kaplan-Meier Estimate[J]. International journal of Ayurveda research. 2010; 1(4): 274-278.
[16]	Jiang X, Cooper GF, Neill DB. Generalized Amoc Curves for Evaluation and Improvement of Event Surveillance. AMIA Annual Symposium proceedings[J]. AMIA Symposium, 2009, 2009: 281-285.
[17]	Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study[J].Lancet (London, England), 2018, 391(10135): 2128-2139.
[18]	Lee CH, Chen LC, Yu CC, et al. Prognostic value of Cd1b in localised prostate cancer[J]. Int J Environ Res Public Health, 2019, 16(23): 4723.
[19]	Liu S, Wang Y, Han Y, et al. Ereg-driven oncogenesis of head and neck squamous cell carcinoma exhibits higher sensitivity to erlotinib therapy[J]. Theranostics, 2020, 10(23): 10589-10605.
[20]	Lei Y, Takahama Y. Xcl1 and Xcr1 in the immune system[J]. Microbes and infection, 2012, 14(3): 262-267.

基因	P值	HR	95%置信区间
基因	P值	HR	下限	上限
TPM2	0.037 333 456	1.164 735 504	1.008 985 34	1.344 527 756
BMP5	0.015 470 686	0.902 244 216	0.830 153 608	0.980 595 18
MAPT	0.048 972 932	1.112 097 744	1.000 478 422	1.236 169 981
SCTR	0.022 720 018	1.153 509 722	1.020 144 019	1.304 310 621
PTH1R	0.001 069 271	1.257 110 43	1.096 076 917	1.441 802 676
NGFR	0.029 119 625	1.118 533 922	1.011 457 652	1.236 945 642
NRG1	0.009 517 37	0.862 798 72	0.771 726 622	0.964 618 311
XCL1	0.017 352 622	1.149 979 461	1.024 927 328	1.290289295
NGF	0.001 577 987	1.271 908 962	1.095 637 576	1.476 539 726
CD1A	0.008 754 914	0.852 017 921	0.755 872 108	0.960 393 339
CD1B	0.001 893 971	0.812 280 797	0.712 418 815	0.926 140 747
PLXNA3	0.011 929 677	1.310 237 479	1.061 376 704	1.617 448 588
IL13RA2	0.017 131 454	0.852 268 15	0.747 304 731	0.971 974 308
OXT	0.026 428 062	1.205 833 49	1.022 155 647	1.422 517 607
PGF	0.038 496 809	1.187 486 309	1.009 138 71	1.397 353 723
TNFRSF19	0.033 426 571	1.107 359 16	1.008 037 142	1.216 467 388
MC1R	0.000 401 155	1.354 699 001	1.145 071 141	1.602 703 375
LTB4R	0.006 024 796	1.257 246 435	1.067 750 88	1.480 372 088
HAMP	0.005 822 998	1.190 324 479	1.051 685 608	1.347 239 473
JAG2	0.038 627 245	1.205 457 908	1.009 821 429	1.438 995 772
LHB	0.003 690 326	1.287 330 466	1.085 538 156	1.526 634 25
NMB	0.037 105 084	1.294 390 61	1.015 548 265	1.649 795 591
VGF	0.019 353 758	1.134 601 004	1.020 658 378	1.261 263 775
GRP	0.028 857 835	1.117 979 089	1.011 571 675	1.235 579 519
INHBB	0.004 117 149	1.160 256 891	1.048 224 983	1.284 262 515
UCN	0.000 868 846	1.356 013 4	1.133 478 922	1.622 237 789
SLC11A1	0.032 705 805	1.146 338 409	1.011 299 872	1.299 408 596
OXTR	0.020 224 425	1.180 831 322	1.026 264 632	1.358 677 449
CXCL1	0.049 032 161	0.878 401 415	0.772 013 438	0.999 4502 78
TDGF1	0.037 335 37	0.917 432 088	0.845 946 482	0.994 958 491
EREG	0.035 366 082	0.924 650 707	0.859 580 693	0.994 646 503
STC2	0.032 651 23	1.130 638 218	1.010 188 758	1.265 449 421

基因	P值	HR	95%置信区间
基因	P值	HR	下限	上限
TPM2	0.037 333 456	1.164 735 504	1.008 985 34	1.344 527 756
BMP5	0.015 470 686	0.902 244 216	0.830 153 608	0.980 595 18
MAPT	0.048 972 932	1.112 097 744	1.000 478 422	1.236 169 981
SCTR	0.022 720 018	1.153 509 722	1.020 144 019	1.304 310 621
PTH1R	0.001 069 271	1.257 110 43	1.096 076 917	1.441 802 676
NGFR	0.029 119 625	1.118 533 922	1.011 457 652	1.236 945 642
NRG1	0.009 517 37	0.862 798 72	0.771 726 622	0.964 618 311
XCL1	0.017 352 622	1.149 979 461	1.024 927 328	1.290289295
NGF	0.001 577 987	1.271 908 962	1.095 637 576	1.476 539 726
CD1A	0.008 754 914	0.852 017 921	0.755 872 108	0.960 393 339
CD1B	0.001 893 971	0.812 280 797	0.712 418 815	0.926 140 747
PLXNA3	0.011 929 677	1.310 237 479	1.061 376 704	1.617 448 588
IL13RA2	0.017 131 454	0.852 268 15	0.747 304 731	0.971 974 308
OXT	0.026 428 062	1.205 833 49	1.022 155 647	1.422 517 607
PGF	0.038 496 809	1.187 486 309	1.009 138 71	1.397 353 723
TNFRSF19	0.033 426 571	1.107 359 16	1.008 037 142	1.216 467 388
MC1R	0.000 401 155	1.354 699 001	1.145 071 141	1.602 703 375
LTB4R	0.006 024 796	1.257 246 435	1.067 750 88	1.480 372 088
HAMP	0.005 822 998	1.190 324 479	1.051 685 608	1.347 239 473
JAG2	0.038 627 245	1.205 457 908	1.009 821 429	1.438 995 772
LHB	0.003 690 326	1.287 330 466	1.085 538 156	1.526 634 25
NMB	0.037 105 084	1.294 390 61	1.015 548 265	1.649 795 591
VGF	0.019 353 758	1.134 601 004	1.020 658 378	1.261 263 775
GRP	0.028 857 835	1.117 979 089	1.011 571 675	1.235 579 519
INHBB	0.004 117 149	1.160 256 891	1.048 224 983	1.284 262 515
UCN	0.000 868 846	1.356 013 4	1.133 478 922	1.622 237 789
SLC11A1	0.032 705 805	1.146 338 409	1.011 299 872	1.299 408 596
OXTR	0.020 224 425	1.180 831 322	1.026 264 632	1.358 677 449
CXCL1	0.049 032 161	0.878 401 415	0.772 013 438	0.999 4502 78
TDGF1	0.037 335 37	0.917 432 088	0.845 946 482	0.994 958 491
EREG	0.035 366 082	0.924 650 707	0.859 580 693	0.994 646 503
STC2	0.032 651 23	1.130 638 218	1.010 188 758	1.265 449 421

Please choose a citation manager

Content to export